233 related articles for article (PubMed ID: 23855221)
1. [Current understanding and perspectives of lymphangioleiomyomatosis].
Seyama K; Ando K; Hoshika Y; Suzuki Y; Takekawa H
Nihon Rinsho; 2013 Jun; 71(6):1103-8. PubMed ID: 23855221
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
5. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.
Sato T; Seyama K; Kumasaka T; Fujii H; Setoguchi Y; Shirai T; Tomino Y; Hino O; Fukuchi Y
J Intern Med; 2004 Aug; 256(2):166-73. PubMed ID: 15257730
[TBL] [Abstract][Full Text] [Related]
6. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
7. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
8. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
9. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.
Fujita A; Ando K; Kobayashi E; Mitani K; Okudera K; Nakashima M; Miyatake S; Tsurusaki Y; Saitsu H; Seyama K; Miyake N; Matsumoto N
Hum Genet; 2016 Jan; 135(1):61-8. PubMed ID: 26563443
[TBL] [Abstract][Full Text] [Related]
10. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
11. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
12. Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice.
Lesma E; Eloisa C; Isaia E; Grande V; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
Am J Pathol; 2012 Sep; 181(3):947-60. PubMed ID: 22770663
[TBL] [Abstract][Full Text] [Related]
13. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
14. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
15. The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.
Steagall WK; Pacheco-Rodriguez G; Darling TN; Torre O; Harari S; Moss J
Am J Respir Cell Mol Biol; 2018 Jun; 58(6):678-683. PubMed ID: 29406787
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
17. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
18. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
19. Human Pluripotent Stem Cell-Derived
Julian LM; Delaney SP; Wang Y; Goldberg AA; Doré C; Yockell-Lelièvre J; Tam RY; Giannikou K; McMurray F; Shoichet MS; Harper ME; Henske EP; Kwiatkowski DJ; Darling TN; Moss J; Kristof AS; Stanford WL
Cancer Res; 2017 Oct; 77(20):5491-5502. PubMed ID: 28830860
[TBL] [Abstract][Full Text] [Related]
20. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
